News
Insights from the frontlines of venture
Insights from the frontlines of venture
News and milestones from 25 years in technology and healthcare.
News and milestones from 25 years in technology and healthcare.
MAR 31, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Read More
Read more
MAR 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
Read More
Read more
MAR 13, 2026
Reframing “SaaS is dead” in the Era of Intelligent Software
Read More
Read more
MAR 10, 2026
Vi Partners welcomes Julien Pache as Partner, Technology
Read More
Read more
JAN 27, 2026
Digital Twins in Oncology
Read More
Read more
JAN 21, 2026
Vi Partners announces first close of its new CHF 150 million fund, reinforcing its long-term commitment to Swiss innovation
Read More
Read more
DEC 05, 2025
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new nonclinical data at ASH
Read More
Read more
DEC 03, 2025
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
Read More
Read more
OCT 27, 2025
Vi Partners celebrates the $3 billion Nexthink valuation, a landmark exit for Swiss Tech
Read More
Read more
OCT 16, 2025
iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO
Read More
Read more
OCT 15, 2025
Vara earns CE mark as the only AI authorized for an independent second read in mammography, and expands in Europe.
Read More
Read more
OCT 08, 2025
Unlocking Europe’s AI Revolution
Read More
Read more
MAR 31, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
Read More
Read more
MAR 18, 2026
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
Read More
Read more
MAR 13, 2026
Reframing “SaaS is dead” in the Era of Intelligent Software
Read More
Read more
MAR 10, 2026
Vi Partners welcomes Julien Pache as Partner, Technology
Read More
Read more
JAN 27, 2026
Digital Twins in Oncology
Read More
Read more
JAN 21, 2026
Vi Partners announces first close of its new CHF 150 million fund, reinforcing its long-term commitment to Swiss innovation
Read More
Read more
DEC 05, 2025
iOnctura initiates Phase I/II trial in patients with myelofibrosis ahead of new nonclinical data at ASH
Read More
Read more
DEC 03, 2025
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
Read More
Read more
OCT 27, 2025
Vi Partners celebrates the $3 billion Nexthink valuation, a landmark exit for Swiss Tech
Read More
Read more